2016

Q1 2016 EARNINGS* Conference Call May 26 at 6:15pm CET

* Not audited



SAFE HARBOR STATEMENT

This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Consequently the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of. For additional information concerning these and other important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the 'Autorité des Marchés Financiers'.





An innovative technology and services company








\times


Our business

 \times





\times Our divisions \times





\times Our R&D \times



Revenue on Capitalized R&D Ratio



as of March 2016

+54%



as of March 2016

+268 bps



\times Our Positions \times



× Our Strengths ×



Leading market positions in each of our divisions



Stable, well-balanced and diversified revenue mix

High barriers to entry



Unique presence in the Healthcare Ecosystem



Recognized portfolio of innovative and integrated solutions



Long-standing shareholder support and experienced

management



Business Group Review





Roadmap for Profitable and Sustainable Growth

Group Transformation

- Management evolution
- Organization change

2016 - 2017

- Change in business model
- Significant investment

2018

- Full benefit of Group transformation
- Well positioned for coming years

2015

- **Disposal** of the *CRM and Strategic Data* division
- Acquisition of Activus and US asset of Nightingale
- Beginning of Cegedim strategic repositioning





Cegedim Investments



Product Update

- Upgrades to reflects market changes
- Introduce new offer





SaaS / Cloud

- All new solutions will be Cloud based
- Will reduce cost of development, maintenance and production
- Drives more recurring
 revenue
- Added value
 proposal



BPO

- Process efficiency
- Flexibility in scaling
- Trends toward more outsourcing



Q1-2016 Financial Situation

cegedim





Revenue €106.2m +5.7% reported +4.8% L-f-L

EBITDA €11.1m (24.6)%

EPS €(1.5)



Group offering shifting to the cloud

Group Cloud and BPO offerings a success

Revenue up Margin impacted

Clean Debt maturity profile

Outlook

Interest expense will reduce by around 9 times over the final 9M of 2016

For 2016 Cegedim expects: at least stable revenue Stability at the EBITDA level



Q1-16 Revenue Growth

Division	Q1-15	L-f-L	Structure	Currency	Reported	Q1-16
Health Insurance H.R. & e-services	53.7	+8.7%	+2.5%	+0.0%	+11.2%	59.7
Healthcare Professionals	45.9	+0.5%		(1.0)%	(0.5)%	45.7
Activities not allocated	0.8	n.m.			(3.8)%	0.8
Cegedim	100.5	+4.8%	+1.3%	(0.5)%	+5.7%	106.2



Well Diversified Revenue Sources



- Strong visibility across direct revenues streams
- Long-term contracts
- High retention rates in all business divisions



Q1-2016 P&L

In € million	Q1-16	Q1-15	% Change
Revenue	106.2	100.5	+ 5.7
EBITDA	11.1	14.7	(24.6)%
margin	<i>10.4%</i>	<i>14.6%</i>	(420)bps
D&A	(8.1)	(7.3)	+10.7%
EBIT before special items	3.0	7.4	(59.4)%
margin	2.8%	7.4%	(454)bps
Special items	(1.1)	(2.9)	(62.0)%
EBIT	1.9	4.6	(57.9)%
margin	<i>1.8%</i>	<i>4.5%</i>	<i>(273)bps</i>
Cost of net financial debt	(23.2)	(6.9)	+236.3%
Total taxes	(0.3)	(0.7)	(58.9)%
Earnings from continuing activities	(21.0)	(2.6)	n.m.
Earnings from discontinued activities	(0.4)	+1.1	n.m.
Net Earnings	(21.4)	(1.5)	n.m.
Earnings per share	(1.5)	(0.1)	n.m.

cegedim

P&L by Division

	Health Insurance H.R. & e-services			Healthcare Professionals			Activities not allocated		
	Q1 16	Q1 15	$\Delta\%$	Q1 16	Q1 15	Δ%	Q1 16	Q1 15	Δ%
Revenue	59.7	53.7	+11.2%	45.7	45.9	(0.5)%	0.8	0.8	n.m.
EBITDA	7.1	8.5	(16.7)%	5.0	6.4	(22.0)%	(1.0)	(0.2)	n.m.
D&A	(3.6)	(3.9)	(7.6)%	(3.2)	(2.9)	+10.7%	(1.3)	(0.5)	n.m.
EBIT before special items	3.5	4.6	(24.5)%	1.8	3.5	(48.6)%	(2.2)	(0.7)	n.m.
	11.8% EBITDA margin		10.9% EBITDA margin			N.M. EBITDA margin			



Health Insurance, H.R. & e-services

Revenue

+8.7% |-f-l

• Double digit growth at

eaedim

- *Cegedim Insurance Solutions* despite the transition to the SaaS/Cloud
- iGestion, BPO activities for Health Insurance C^{ies}
- *Cegedim SRH* SaaS platform for HR management
- *GIS* SaaS platform for electronic data flows including payment platforms (*Cegedim e-business*)
- Significant growth at managing third-party payer flows
- Revenue also bolstered by the acquisition of *Activus*

EBITDA

(16.7)%

- Temporary decline in profitability at:
 - *iGestion* and *Cegedim e-business* due to the start of business with numerous BPO clients
 - *RNP* suffered from a change in the timing of promotional campaigns between 2015 and 2016
- This was partly offset by the good performance of:
 - Business of managing third-party payer flows
 - Cegedim SRH
 - Cegedim Insurance Solutions



Healthcare Professionals

+0.5% |-f-|

Revenue

- Growth of more than 60% at Pulse Systems owing to a successful rollout of its RCM offering and EHR offering
- Growth in the *Claude Bernard* medication database, whose sales are also growing in the UK
- This positive trend was partially offset by a slowdown in the UK doctor computerization business.
- New cloud software for French pharmacists launched in May 2016

EBITDA

(22.0)%

- Decline due to investment made to ensure future growth
 - Chiefly by the investment done for the cloud software for French pharmacists
- This trend was partly offset growth at the RCM and EHR activities in the US





Managing the debt profile

New RCF facility of €200m with a 5 years maturity. Signed on January 2016.

Shareholder loan: maturity extended to Jan. 2021.

6.75% bond 2020: Full redemption done on Q1 2016.



Consolidated Balance Sheet (in €m)

Assets	Mar. 16	Dec. 15		
Goodwill	185.8	188.5		
Other non-current assets	226.3	223.7		
Cash & cash equivalents	20.2	231.3		
Other current assets	233.1	220.0		
Assets held for sale	1.4	0.8		
Shareholders Equity & Liabilities				
Shareholders Equity ⁽¹⁾	200.0	228.1		
Other non-current liabilities	44.2	44.3		
Financial debt ⁽²⁾	229.6	398.9		
Other current liabilities	192.4	189.1		
Liabilities of activities held for sale	0.5	3.8		



(1) Including minority interest(2) Long-term and short-term deb

Net Debt Situation






Net total debt include liabilities under our employee profit sharing plans for €8,3m on March 31,2016 and for €8.3m on December 31, 2015 Paid for the total redemption of the 6,75% bond maturing in 2020

23

Solid Capital Structure



egedim

This includes 0.3% of the shares of Cegedim S.A held by Cegedim S.A. as of March 31, 2016



Group transformation continue
 Robust investment in R&D maintained for 2016
 Transition to SaaS and BPO deployment
 For 2016, Cegedim expects⁽¹⁾ at least stable revenue from continuing activities and stability at the EBITDA level.

(1) These projections are publicly disclosed on May 26, 2016. the fact that Cegedim include these projections in this presentation should not be taken to mean that these projections continue to be our projections as of any subsequent date. Please refer to point 3,7 "Outlook" in our 2015 Registration Document



Appendix





Cegelease activity has evolved:

In 2001	In 2015
Exclusive reseller of Group's products	Broker of financial leases
Cegedim: unique supplier	Many different suppliers
Payment solution for Pharmacist	Financing solutions for all healthcare professionals and others professionals
All contracts are self-financed	Majority of contract are resold to banks
Cegelease bears all the risk	The majority of risk is transferred to banks



Q1 2015 Revenue Restatement by Division

	Reported Mar. 2015	Restatement	Restated Mar. 2015
Health Insurance H.R. & e-services	54.0	(0,3) ⁽¹⁾	53.7
Healthcare Professionals	37.2	8.7	45.9
Cegelease	29.3	(29.3)	
Activities not allocated	0.8		0.8
Cegedim	121.3	(20.8)	100.4



Cegelase's Restatement Impact

This leads to a restatement of Q1 2015 accounts in accordance with IAS 17. Impact on Revenue, EBITDA but not on EBIT









We welcome your questions and comments

Jan Eryk Umiastowski Chief Investment Officer – Head of Investor Relations

janeryk.umiastowski@cegedim.com Tel: 00 33 1 49 09 33 36 – Mob: 00 33 6 73 25 96 34